Integrated Filing — IndAS


General information about company

Scrip Code 540596
NSE Symbol ERIS
MSEI Symbol NOTLISTED
ISIN INE406M01024
Name of company Eris Lifesciences Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 19-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 13-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 19-May-2025   11:00:00
End date and time of board meeting 19-May-2025   15:55:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? Yes
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication? Yes
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2023-08-07
Indicate Company website link for updated RPT policy of the Company www.eris.co.in/corporate-governance
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
The Company has not defaulted on loans and debt securities



Financial Results Ind-AS

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 4047700000 16977500000
Other income 167500000 355100000
Total income 4215200000 17332600000
2 Expenses
(a) Cost of materials consumed 98300000 683500000
(b) Purchases of stock-in-trade 1190200000 4744400000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -45300000 -435400000
(d) Employee benefit expense 814100000 3619200000
(e) Finance costs 531600000 2202400000
(f) Depreciation, depletion and amortisation expense 433800000 1817700000
(f) Other Expenses
1 Other expenses 780700000 3500300000
Total other expenses 780700000 3500300000
Total expenses 3803400000 16132100000
3 Total profit before exceptional items and tax 411800000 1200500000
4 Exceptional items 0 0
5 Total profit before tax 411800000 1200500000
6 Tax expense
7 Current tax 85100000 219800000
8 Deferred tax 22000000 206800000
9 Total tax expenses 107100000 426600000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 304700000 773900000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 304700000 773900000
17 Other comprehensive income net of taxes -15900000 -28400000
18 Total Comprehensive Income for the period 288800000 745500000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 136200000 136200000
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve 25012800000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 2.24 5.69
Diluted earnings (loss) per share from continuing operations 2.23 5.68
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 2.24 5.69
Diluted earnings (loss) per share from continuing and discontinued operations 2.23 5.68
24 Debt equity ratio 0.0089 0.0089
25 Debt service coverage ratio 0.0152 0.0148
26 Interest service coverage ratio 0.0177 0.0155
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 1071700000
Capital work-in-progress 0
Investment property
Goodwill 485700000
Other intangible assets 22564400000
Intangible assets under development 2700000
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments 9912700000
Trade receivables, non-current
Loans, non-current 2491100000
Other non-current financial assets 6390600000
Total non-current financial assets 18794400000
Deferred tax assets (net) 2833600000
Other non-current assets 196400000
Total non-current assets 45948900000
2 Current assets
Inventories 1912500000
Current financial asset
Current investments 0
Trade receivables, current 2361900000
Cash and cash equivalents 843400000
Bank balance other than cash and cash equivalents 81200000
Loans, current 140100000
Other current financial assets 72000000
Total current financial assets 3498600000
Current tax assets (net)
Other current assets 864300000
Total current assets 6275400000
3 Non-current assets classified as held for sale 0
4 Regulatory deferral account debit balances and related deferred tax Assets 0
Total assets 52224300000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 136200000
Other equity 25012800000
Total equity attributable to owners of parent 25149000000
Non controlling interest
Total equity 25149000000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 16326400000
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 220100000
Total non-current financial liabilities 16546500000
Provisions, non-current 579800000
Deferred tax liabilities (net)
Deferred government grants, Non-current
Other non-current liabilities 9600000
Total non-current liabilities 17135900000
Current liabilities
Current financial liabilities
Borrowings, current 5803100000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 30600000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 2130200000
Total Trade payable 2160800000
Other current financial liabilities 1366800000
Total current financial liabilities 9330700000
Other current liabilities 159500000
Provisions, current 392600000
Current tax liabilities (Net) 56600000
Deferred government grants, Current
Total current liabilities 9939400000
3 Liabilities directly associated with assets in disposal group classified as held for sale 0
4 Regulatory deferral account credit balances and related deferred tax liability 0
Total liabilities 27075300000
Total equity and liabilites 52224300000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit or loss -11800000 -31000000
Total Amount of items that will not be reclassified to profit and loss -11800000 -31000000
2 Income tax relating to items that will not be reclassified to profit or loss 4100000 -2600000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income -15900000 -28400000



Cash flow statement, indirect

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 2024-04-01
B Date of end of reporting period 2025-03-31
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 1200500000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 2202400000
Adjustments for decrease (increase) in inventories -494700000
Adjustments for decrease (increase) in trade receivables, current 313100000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets 1360300000
Adjustments for decrease (increase) in other non-current assets 0
Adjustments for other financial assets, non-current 0
Adjustments for other financial assets, current 0
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current 789400000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities -21500000
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 1817700000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 74000000
Adjustments for provisions, non-current 0
Adjustments for other financial liabilities, current -3700000
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains 0
Adjustments for dividend income 0
Adjustments for interest income 150500000
Adjustments for share-based payments 91300000
Adjustments for fair value losses (gains) -30000000
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items 4700000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) 5952500000
Net cash flows from (used in) operations 7153000000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 134300000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 7018700000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 14065000000
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 0
Purchase of property, plant and equipment 76200000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 2000000
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 11200000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 10538100000
Net cash flows from (used in) investing activities -3589900000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 72300000
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 3904000000
Repayments of borrowings 3542900000
Payments of lease liabilities 61600000
Dividends paid 1000500000
Interest paid 1252000000
Income taxes paid (refund) 0
Other inflows (outflows) of cash -1224000000
Net cash flows from (used in) financing activities -3104700000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 324100000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents 324100000
Cash and cash equivalents cash flow statement at beginning of period 519300000
Cash and cash equivalents cash flow statement at end of period 843400000







Details of Impact of Audit Qualification

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Deloitte Haskins & Sells LLP Yes 31-Jul-2027


Financial details

Sr. Particulars Audited Figures (as reported before adjusting for qualifications) Adjusted Figures (audited figures after adjusting for qualifications)
1 Turnover / Total income
2 Total Expenditure
3 Net Profit/(Loss)
4 Earnings Per Share
5 Total Assets
6 Total Liabilities
7 Net Worth




Signatories detail

Name of CEO / Managing director
Name of CFO
Name of audit committee chairman
Name of statutory auditor
Name of other signatory, if any, with designation
Place
Date



Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity /subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 APRICA HEALTHCARE LTD ERIS HEALTHCARE PVT LTD Group Company Interest received 0 NA 6200000 0 0
2 APRICA HEALTHCARE LTD ERIS HEALTHCARE PVT LTD Group Company Any other transaction Royalty income 0 NA 600000 0 0
3 APRICA HEALTHCARE LTD ERIS LIFESCIENCES LTD Holding Company Any other transaction Royalty income 0 NA 800000 0 0
4 APRICA HEALTHCARE LTD ERIS THERAPEUTICS LTD Holding Company Any other transaction Royalty income 0 NA 200000 0 0
5 ERIS M.J. BIOPHARM PVT LTD ERIS LIFESCIENCES LTD Holding Company Sale of goods or services 2000000000 Approved on 25 Oct 2025 97300000 0 0
6 ERIS LIFESCIENCES LTD APRICA HEALTHCARE LTD Group Company Any other transaction Cross charge operating income 0 NA 1700000 0 0
7 ERIS LIFESCIENCES LTD APRICA HEALTHCARE LTD Group Company Interest received 0 NA 2800000 0 0
8 ERIS LIFESCIENCES LTD APRICA HEALTHCARE LTD Group Company Any other transaction Royalty income 0 NA 6100000 0 0
9 ERIS LIFESCIENCES LTD APRICA HEALTHCARE LTD Group Company Sale of goods or services 0 NA 48900000 0 0
10 ERIS LIFESCIENCES LTD ERIS BIONXT PRIVATE LIMITED Wholly Owned Subsidiary Interest received 0 NA 51000000 0 0
11 ERIS LIFESCIENCES LTD ERIS BIONXT PRIVATE LIMITED Wholly Owned Subsidiary Any other transaction RM PM Sales 0 NA 412300000 0 0
12 ERIS LIFESCIENCES LTD ERIS HEALTHCARE PVT LTD Wholly Owned Subsidiary Any other transaction Cross charge operating income 0 NA 1800000 0 0
13 ERIS LIFESCIENCES LTD ERIS HEALTHCARE PVT LTD Wholly Owned Subsidiary Interest received 0 NA 200000 0 0
14 ERIS LIFESCIENCES LTD ERIS HEALTHCARE PVT LTD Wholly Owned Subsidiary Any other transaction Royalty income 0 NA 1000000 0 0
15 ERIS LIFESCIENCES LTD ERIS HEALTHCARE PVT LTD Wholly Owned Subsidiary Sale of goods or services 0 NA 60700000 0 0
16 ERIS LIFESCIENCES LTD ERIS M.J. BIOPHARM PVT LTD Subsidiary Any other transaction Cross charge operating income 2000000000 Approved on 25 Oct 2025 1700000 0 0
17 ERIS LIFESCIENCES LTD ERIS M.J. BIOPHARM PVT LTD Subsidiary Interest received 2000000000 Approved on 25 Oct 2025 15200000 0 0
18 ERIS LIFESCIENCES LTD ERIS M.J. BIOPHARM PVT LTD Subsidiary Sale of goods or services 2000000000 Approved on 25 Oct 2025 14700000 0 0
19 ERIS LIFESCIENCES LTD ERIS THERAPEUTICS LTD Wholly Owned Subsidiary Any other transaction Cross charge operating income 0 NA 70400000 0 0
20 ERIS LIFESCIENCES LTD ERIS THERAPEUTICS LTD Wholly Owned Subsidiary Interest received 0 NA 44700000 0 0
21 ERIS LIFESCIENCES LTD ERIS THERAPEUTICS LTD Wholly Owned Subsidiary Any other transaction RM PM Sales 0 NA 3200000 0 0
22 ERIS LIFESCIENCES LTD ERIS THERAPEUTICS LTD Wholly Owned Subsidiary Any other transaction Royalty income 0 NA 166500000 0 0
23 ERIS LIFESCIENCES LTD ERIS THERAPEUTICS LTD Wholly Owned Subsidiary Sale of goods or services 0 NA 300000 0 0
24 ERIS THERAPEUTICS LTD ERIS HEALTHCARE PVT LTD Group Company Interest received 0 NA 1100000 0 0
25 ERIS THERAPEUTICS LTD ERIS LIFESCIENCES LTD Holding Company Any other transaction Cross charge operating income 0 NA 5600000 0 0
26 ERIS THERAPEUTICS LTD ERIS LIFESCIENCES LTD Holding Company Interest received 0 NA 22000000 0 0
27 ERIS THERAPEUTICS LTD ERIS LIFESCIENCES LTD Holding Company Any other transaction RM PM Sales 0 NA 15400000 0 0
28 ERIS THERAPEUTICS LTD ERIS LIFESCIENCES LTD Holding Company Sale of goods or services 0 NA 4800000 0 0
29 ERIS OAKNET HELATHCATE PVT LTD APRICA HEALTHCARE LTD Group Company Interest received 0 NA 100000 0 0
30 ERIS OAKNET HELATHCATE PVT LTD ERIS HEALTHCARE PVT LTD Group Company Any other transaction Royalty income 0 NA 100000 0 0
31 ERIS OAKNET HELATHCATE PVT LTD ERIS LIFESCIENCES LTD Group Company Interest received 0 NA 6200000 0 0
32 ERIS OAKNET HELATHCATE PVT LTD ERIS LIFESCIENCES LTD Group Company Any other transaction Royalty income 0 NA 3000000 0 0
33 ERIS OAKNET HELATHCATE PVT LTD ERIS LIFESCIENCES LTD Group Company Sale of goods or services 0 NA 8500000 0 0
34 ERIS OAKNET HELATHCATE PVT LTD ERIS LIFESCIENCES LTD Group Company Any other transaction Royalty income 0 NA 4800000 0 0
35 SWISS PARENTERALS LTD ERIS LIFESCIENCES LTD Holding Company Interest received 2000000000 Approved on 13 Feb 2024 1400000 0 0
36 SWISS PARENTERALS LTD ERIS LIFESCIENCES LTD Holding Company Sale of goods or services 2000000000 Approved on 13 Feb 2024 43900000 0 0
37 APRICA HEALTHCARE LTD ERIS HEALTHCARE PVT LTD Group Company Any other transaction loan closing balance 0 NA 0 357200000 5600000
38 APRICA HEALTHCARE LTD ERIS HEALTHCARE PVT LTD Group Company Any other transaction Bond 0 NA 0 30000000 30000000
39 APRICA HEALTHCARE LTD ERIS HEALTHCARE PVT LTD Group Company Advance 0 NA 0 0 0
40 APRICA HEALTHCARE LTD ERIS M.J. BIOPHARM PVT LTD Group Company Any other transaction loan closing balance 2000000000 Approved on 25 Oct 2025 0 0 75900000
41 APRICA HEALTHCARE LTD ERIS LIFESCIENCES LTD Group Company Any other transaction loan closing balance 0 NA 0 0 80000000
42 APRICA HEALTHCARE LTD ERIS M.J. BIOPHARM PVT LTD Group Company Any other transaction other current financial assets 2000000000 Approved on 25 Oct 2025 0 0 9100000
43 APRICA HEALTHCARE LTD ERIS HEALTHCARE PVT LTD Group Company Any other transaction Trade receivables 0 NA 0 0 217000000
44 APRICA HEALTHCARE LTD ERIS LIFESCIENCES LTD Group Company Any other transaction Trade receivables 0 NA 0 0 1700000
45 APRICA HEALTHCARE LTD ERIS THERAPEUTICS LTD Holding Company Any other transaction Trade receivables 0 NA 0 0 400000
46 ERIS BIONXT PRIVATE LIMITED ERIS LIFESCIENCES LTD Holding Company Advance 0 NA 0 0 500000
47 ERIS HEALTHCARE PVT LTD APRICA HEALTHCARE LTD Group Company Advance 0 NA 0 0 0
48 ERIS HEALTHCARE PVT LTD ERIS LIFESCIENCES LTD Holding Company Advance 0 NA 0 0 1400000
49 ERIS HEALTHCARE PVT LTD Eris Pharmaceutical Limited Group Company Any other transaction loan closing balance 0 NA 0 200000 200000
50 ERIS HEALTHCARE PVT LTD APRICA HEALTHCARE LTD Group Company Any other transaction Trade receivables 0 NA 0 0 900000
51 ERIS M.J. BIOPHARM PVT LTD ERIS LIFESCIENCES LTD Holding Company Advance 2000000000 Approved on 25 Oct 2025 0 0 4900000
52 ERIS M.J. BIOPHARM PVT LTD ERIS THERAPEUTICS LTD Group Company Any other transaction Trade receivables 2000000000 Approved on 25 Oct 2025 0 200000 0
53 ERIS M.J. BIOPHARM PVT LTD ERIS LIFESCIENCES LTD Group Company Any other transaction Trade receivables 2000000000 Approved on 25 Oct 2025 0 13900000 0
54 ERIS LIFESCIENCES LTD ERIS THERAPEUTICS LTD Wholly Owned Subsidiary Any other transaction Accrued Interest Receivable 0 NA 0 0 44700000
55 ERIS LIFESCIENCES LTD ERIS M.J. BIOPHARM PVT LTD Subsidiary Advance 2000000000 Approved on 25 Oct 2025 0 0 0
56 ERIS LIFESCIENCES LTD ERIS OAKNET HELATHCATE PVT LTD Group Company Advance 0 NA 0 0 200000
57 ERIS LIFESCIENCES LTD SWISS PARENTERALS LTD Subsidiary Advance 2000000000 Approved on 13 feb 2024 0 0 8400000
58 ERIS LIFESCIENCES LTD APRICA HEALTHCARE LTD Group Company Any other transaction Bond 0 NA 200000000 200000000 0
59 ERIS LIFESCIENCES LTD APRICA HEALTHCARE LTD Group Company Any other transaction loan closing balance 0 NA 0 178400000 2500000
60 ERIS LIFESCIENCES LTD ERIS BIONXT PRIVATE LIMITED Wholly Owned Subsidiary Any other transaction loan closing balance 0 NA 0 0 2480300000
61 ERIS LIFESCIENCES LTD ERIS HEALTHCARE PVT LTD Wholly Owned Subsidiary Any other transaction loan closing balance 0 NA 0 1500000 1700000
62 ERIS LIFESCIENCES LTD ERIS M.J. BIOPHARM PVT LTD Subsidiary Any other transaction loan closing balance 2000000000 Approved on 25 Oct 2025 0 364700000 123000000
63 ERIS LIFESCIENCES LTD ERIS THERAPEUTICS LTD Wholly Owned Subsidiary Any other transaction other current financial assets 0 NA 0 0 6321900000
64 ERIS LIFESCIENCES LTD APRICA HEALTHCARE LTD Group Company Any other transaction Trade receivables 0 NA 0 2400000 8700000
65 ERIS LIFESCIENCES LTD ERIS HEALTHCARE PVT LTD Wholly Owned Subsidiary Any other transaction Trade receivables 0 NA 0 1500000 1100000
66 ERIS LIFESCIENCES LTD ERIS M.J. BIOPHARM PVT LTD Subsidiary Any other transaction Trade receivables 2000000000 Approved on 25 Oct 2025 0 300000 0
67 ERIS LIFESCIENCES LTD ERIS THERAPEUTICS LTD Wholly Owned Subsidiary Any other transaction Trade receivables 0 NA 0 0 181500000
68 ERIS LIFESCIENCES LTD SWISS PARENTERALS LTD Subsidiary Any other transaction Trade receivables 2000000000 Approved on 13 feb 2024 0 0 2100000
69 ERIS THERAPEUTICS LTD ERIS HEALTHCARE PVT LTD Group Company Any other transaction loan closing balance 0 NA 0 0 377500000
70 ERIS THERAPEUTICS LTD ERIS LIFESCIENCES LTD Holding Company Any other transaction loan closing balance 0 NA 0 1037900000 15700000
71 ERIS THERAPEUTICS LTD ERIS LIFESCIENCES LTD Holding Company Any other transaction Trade receivables 0 NA 0 700000 0
72 ERIS THERAPEUTICS LTD ERIS HEALTHCARE PVT LTD Group Company Any other transaction Trade receivables 0 NA 0 0 158000000
73 ERIS THERAPEUTICS LTD ERIS OAKNET HELATHCATE PVT LTD Wholly Owned Subsidiary Any other transaction Trade receivables 0 NA 0 0 0
74 ERIS OAKNET HELATHCATE PVT LTD ERIS LIFESCIENCES LTD Holding Company Advance 0 NA 0 0 300000
75 ERIS OAKNET HELATHCATE PVT LTD APRICA HEALTHCARE LTD Group Company Any other transaction loan closing balance 0 NA 0 2100000 2100000
76 ERIS OAKNET HELATHCATE PVT LTD ERIS LIFESCIENCES LTD Group Company Any other transaction loan closing balance 0 NA 0 309800000 340700000
77 ERIS OAKNET HELATHCATE PVT LTD ERIS LIFESCIENCES LTD Group Company Any other transaction Trade receivables 0 NA 0 21300000 31600000
78 ERIS OAKNET HELATHCATE PVT LTD ERIS THERAPEUTICS LTD Holding Company Any other transaction Trade receivables 0 NA 0 0 7600000
79 SWISS PARENTERALS LTD ERIS LIFESCIENCES LTD Holding Company Any other transaction loan closing balance 2000000000 Approved on 13 feb 2024 0 0 988600000
80 SWISS PARENTERALS LTD ERIS BIONXT PRIVATE LIMITED Group Company Any other transaction Trade receivables 2000000000 Approved on 13 feb 2024 0 0 2700000
81 SWISS PARENTERALS LTD ERIS LIFESCIENCES LTD Group Company Any other transaction Trade receivables 2000000000 Approved on 13 feb 2024 0 0 13900000
82 SWISS PARENTERALS LTD ERIS THERAPEUTICS LTD Group Company Any other transaction Trade receivables 2000000000 Approved on 13 feb 2024 0 4500000 1800000
83 APRICA HEALTHCARE LTD ERIS LIFESCIENCES LTD Group Company Loan 0 NA 7900000 0 0 Loan 0.08 On Demand Unsecured Working Capital
84 APRICA HEALTHCARE LTD ERIS OAKNET HEALTHCARE PVT LTD Group Company Loan 0 NA 100000 0 0 Loan 0.08 On Demand Unsecured Working Capital
85 ERIS BIONXT PRIVATE LIMITED ERIS LIFESCIENCES LTD Holding Company Loan 0 NA 3078500000 0 0 Loan 0.08 On Demand Unsecured Working Capital
86 ERIS HEALTHCARE PVT LTD APRICA HEALTHCARE LTD Group Company Loan 0 NA 16900000 0 0 Loan 0.08 On Demand Unsecured Working Capital
87 ERIS HEALTHCARE PVT LTD ERIS LIFESCIENCES LTD Holding Company Loan 0 NA 30200000 0 0 Loan 0.08 On Demand Unsecured Working Capital
88 ERIS HEALTHCARE PVT LTD ERIS THERAPEUTICS LTD Group Company Loan 0 NA 379600000 0 0 Loan 0.08 On Demand Unsecured Working Capital
89 ERIS M.J. BIOPHARM PVT LTD APRICA HEALTHCARE LTD Group Company Loan 2000000000 Approved on 25 Oct 2025 75900000 0 0 Loan 0.08 On Demand Unsecured Working Capital
90 ERIS M.J. BIOPHARM PVT LTD ERIS LIFESCIENCES LTD Holding Company Loan 2000000000 Approved on 25 Oct 2025 321300000 0 0 Loan 0.08 On Demand Unsecured Working Capital
91 ERIS LIFESCIENCES LTD APRICA HEALTHCARE LTD Group Company Loan 0 NA 80000000 0 0 Loan 0.08 On Demand Unsecured Working Capital
92 ERIS LIFESCIENCES LTD ERIS OAKNET HEALTHCARE PVT LTD Group Company Loan 0 NA 65500000 0 0 Loan 0.08 On Demand Unsecured Working Capital
93 ERIS LIFESCIENCES LTD ERIS OAKNET HELATHCATE PVT LTD Group Company Loan 0 NA 100000 0 0 Loan 0.08 On Demand Unsecured Working Capital
94 ERIS LIFESCIENCES LTD ERIS THERAPEUTICS LTD Wholly Owned Subsidiary Loan 0 NA 5554400000 0 0 Loan 0.08 On Demand Unsecured Working Capital
95 ERIS LIFESCIENCES LTD SWISS PARENTERALS LTD Subsidiary Loan 2000000000 Approved on 13 feb 2024 1018600000 0 0 Loan 0.08 On Demand Unsecured Working Capital
96 APRICA HEALTHCARE LTD ERIS LIFESCIENCES LTD Group Company Loan 0 NA 183800000 0 0
97 ERIS BIONXT PRIVATE LIMITED ERIS LIFESCIENCES LTD Holding Company Loan 0 NA 1331000000 0 0
98 ERIS HEALTHCARE PVT LTD APRICA HEALTHCARE LTD Group Company Loan 0 NA 368500000 0 0
99 ERIS HEALTHCARE PVT LTD ERIS LIFESCIENCES LTD Holding Company Loan 0 NA 30000000 0 0
100 ERIS HEALTHCARE PVT LTD ERIS THERAPEUTICS LTD Group Company Loan 0 NA 2100000 0 0
101 ERIS M.J. BIOPHARM PVT LTD ERIS LIFESCIENCES LTD Holding Company Loan 2000000000 Approved on 25 Oct 2025 563000000 0 0
102 ERIS LIFESCIENCES LTD ERIS OAKNET HEALTHCARE PVT LTD Group Company Loan 0 NA 34500000 0 0
103 ERIS LIFESCIENCES LTD ERIS THERAPEUTICS LTD Wholly Owned Subsidiary Loan 0 NA 6576700000 0 0
104 ERIS LIFESCIENCES LTD SWISS PARENTERALS LTD Subsidiary Loan 2000000000 Approved on 13 feb 2024 30000000 0 0
105 APRICA HEALTHCARE LTD ERIS HEALTHCARE PVT LTD Group Company Loan 0 NA 16900000 0 0 Loan 0.08 On demand Unsecured Working Capital
106 APRICA HEALTHCARE LTD ERIS LIFESCIENCES LIMITED Group Company Loan 0 NA 80000000 0 0 Loan 0.08 On demand Unsecured Working Capital
107 APRICA HEALTHCARE LTD ERIS M.J. BIOPHARM PVT LTD Group Company Loan 2000000000 Approved on 25 feb 2025 75900000 0 0 Loan 0.08 On demand Unsecured Working Capital
108 ERIS LIFESCIENCES LTD APRICA HEALTHCARE LTD Group Company Loan 0 NA 5400000 0 0 Loan 0.08 On demand Unsecured Working Capital
109 ERIS LIFESCIENCES LTD ERIS BIONXT PRIVATE LIMITED Wholly Owned Subsidiary Loan 0 NA 1773100000 0 0 Loan 0.08 On demand Unsecured Working Capital
110 ERIS LIFESCIENCES LTD ERIS HEALTHCARE PVT LTD Wholly Owned Subsidiary Loan 0 NA 130200000 0 0 Loan 0.08 On demand Unsecured Working Capital
111 ERIS LIFESCIENCES LTD ERIS M.J. BIOPHARM PVT LTD Subsidiary Loan 2000000000 Approved on 25 Oct 2025 216300000 0 0 Loan 0.08 On demand Unsecured Working Capital
112 ERIS THERAPEUTICS LTD ERIS HEALTHCARE PVT LTD Group Company Loan 0 NA 478500000 0 0 Loan 0.08 On demand Unsecured Working Capital
113 ERIS THERAPEUTICS LTD ERIS LIFESCIENCES LIMITED Holding Company Loan 0 NA 6261400000 0 0 Loan 0.08 On demand Unsecured Working Capital
114 APRICA HEALTHCARE LTD ERIS HEALTHCARE PVT LTD Group Company Loan 0 NA 368500000 0 0
115 ERIS LIFESCIENCES LTD APRICA HEALTHCARE LTD Group Company Loan 0 NA 181300000 0 0
116 ERIS LIFESCIENCES LTD ERIS BIONXT PRIVATE LIMITED Wholly Owned Subsidiary Loan 0 NA 25600000 0 0
117 ERIS LIFESCIENCES LTD ERIS HEALTHCARE PVT LTD Wholly Owned Subsidiary Loan 0 NA 130000000 0 0
118 ERIS LIFESCIENCES LTD ERIS M.J. BIOPHARM PVT LTD Subsidiary Loan 2000000000 Approved on 25 Oct 2025 458000000 0 0
119 ERIS THERAPEUTICS LTD ERIS HEALTHCARE PVT LTD Group Company Loan 0 NA 100900000 0 0
120 ERIS THERAPEUTICS LTD ERIS LIFESCIENCES LIMITED Holding Company Loan 0 NA 7283700000 0 0
121 Eris Pharmaceuticals Limited Madhav Biscuits Private Limited Entity of related party Loan 0 NA 0 100000 100000
122 ERIS LIFESCIENCES LTD Parv Amit Bakshi relative of related party Remuneration 4000000 NA 1700000 200000 200000
123 ERIS LIFESCIENCES LTD Sarthak Negi relative of related party Remuneration 400000 NA 200000 0 0
124 ERIS LIFESCIENCES LTD Milind Talegaonkar Company Secretary of Eris Lifesciences Ltd. Remuneration 5100000 Approved on 22 May 24 2200000 300000 300000
125 ERIS LIFESCIENCES LTD Sachin Shah CFO of Eris Lifesciences Ltd. Remuneration 17800000 Approved on 22 May 24 8600000 900000 900000
126 ERIS LIFESCIENCES LTD Shreya Mohan CS of Eris Oaknet Healthcare P. Ltd. Remuneration 0 NA 700000 100000 100000
127 ERIS LIFESCIENCES LTD Gagan Atreja Director of Subsidiary Remuneration 0 NA 600000 900000 0
128 ERIS LIFESCIENCES LTD Amit Bakshi Director of Eris Lifesciences Ltd. Remuneration 0 NA 28500000 2500000 2500000
129 ERIS LIFESCIENCES LTD Inderjeet Singh Negi Director of Eris Lifesciences Ltd. Remuneration 0 NA 7200000 700000 700000
130 ERIS LIFESCIENCES LTD Kaushal Shah Director of Eris Lifesciences Ltd. Remuneration 0 Approved on 12 Oct 2024 9000000 700000 1100000
131 ERIS LIFESCIENCES LTD Krishnakumar Vaidyanathan Director of Eris Lifesciences Ltd. Remuneration 0 NA 27000000 300000 2400000
132 ERIS LIFESCIENCES LTD Rajendra Patel Promoter of Eris Lifesciences Ltd. Remuneration 0 NA 3200000 2400000 300000
133 ERIS LIFESCIENCES LTD Milind Talegaonkar Company Secretary of Eris Lifesciences Ltd. Any other transaction Reimbursement of expenses 0 NA 1800000 300000 300000
134 ERIS LIFESCIENCES LTD Sachin Shah CFO of Eris Lifesciences Ltd. Any other transaction Reimbursement of expenses 0 NA 1800000 300000 300000
135 ERIS LIFESCIENCES LTD Parv Amit Bakshi relative of related party Any other transaction Reimbursement of expenses 0 NA 1800000 300000 300000
136 ERIS LIFESCIENCES LTD Amit Bakshi Director of Eris Lifesciences Ltd. Any other transaction Reimbursement of expenses 0 NA 1800000 300000 300000
137 ERIS LIFESCIENCES LTD Kaushal Shah Director of Eris Lifesciences Ltd. Any other transaction Reimbursement of expenses 0 NA 1800000 300000 300000
138 ERIS LIFESCIENCES LTD Inderjeet Singh Negi Director of Eris Lifesciences Ltd. Any other transaction Reimbursement of expenses 0 NA 1800000 300000 300000
139 ERIS LIFESCIENCES LTD Rajendra Patel Promoter of Eris Lifesciences Ltd. Any other transaction Reimbursement of expenses 0 NA 1800000 300000 300000
140 ERIS LIFESCIENCES LTD Krishnakumar Vaidyanathan Director of Eris Lifesciences Ltd. Any other transaction Reimbursement of expenses 0 NA 1800000 300000 300000
141 ERIS LIFESCIENCES LTD Shreya Mohan CS of Eris Oaknet Healthcare P. Ltd. Any other transaction Reimbursement of expenses 0 NA 1800000 300000 300000
142 ERIS LIFESCIENCES LTD Gagan Atreja Director of Subsidiary Any other transaction Reimbursement of expenses 0 NA 0 300000 0
143 ERIS LIFESCIENCES LTD RMS Infraspace Private Limited Entity of related party Any other transaction Rent Paid 2000000000 Approved on 17 May 23 400000 0 100000
144 ERIS LIFESCIENCES LTD RMS Infraspace Private Limited Entity of related party Any other transaction Security Deposit 2000000000 Approved on 17 May 23 0 28500000 28500000
145 SWISS PARENTERALS LTD SWISS PHARMA PVT LTD Entity of related party Purchase of goods or services 0 NA 1400000 0 0
146 SWISS PARENTERALS LTD DEUTSCHE LABS INC Entity of related party Purchase of goods or services 0 NA 8500000 0 0
147 SWISS PARENTERALS LTD SWISS EXPORTS PVT LTD Entity of related party Sale of goods or services 0 NA 0 0 0
148 SWISS PARENTERALS LTD DEUTSCHE LABS INC Entity of related party Sale of goods or services 0 NA 27600000 0 0
149 SWISS PARENTERALS LTD SWISS EXPORTS PVT LTD Entity of related party Any other transaction RM PM Sales 0 NA 1500000 0 0
150 SWISS PARENTERALS LTD DEUTSCHE LABS INC Entity of related party Any other transaction RM PM Sales 0 NA 0 0 0
151 SWISS PARENTERALS LTD SYNER MEDICO PVT LTD Entity of related party Sale of goods or services 0 NA 0 0 0
152 SWISS PARENTERALS LTD NAISHADH V SHAH Director of Swiss Parenterals Remuneration 0 NA 23600000 0 0
153 SWISS PARENTERALS LTD PIYUSH THAKKAR CFO of Swiss Parenterals Remuneration 0 NA 2300000 0 0
154 SWISS PARENTERALS LTD HEALTHBEST PVT LTD Entity of related party Any other transaction Rent Paid 0 NA 900000 0 0
155 SWISS PARENTERALS LTD DEUTSCHE LABS INC Entity of related party Any other transaction Sales return 0 NA 61600000 0 0
156 SWISS PARENTERALS LTD DEUTSCHE LABS INC Entity of related party Any other transaction Trade Payables 0 NA 0 0 9500000
157 SWISS PARENTERALS LTD SWISS PHARMA PVT LTD Entity of related party Any other transaction Trade Payables 0 NA 0 1200000 0
158 SWISS PARENTERALS LTD HEALTHBEST PVT LTD Entity of related party Any other transaction Trade Payables 0 NA 0 0 500000
159 SWISS PARENTERALS LTD SWISS EXPORTS PVT LTD Entity of related party Any other transaction Trade receivables 0 NA 0 600000 0
160 SWISS PARENTERALS LTD DEUTSCHE LABS INC Entity of related party Any other transaction Trade receivables 0 NA 0 68900000 0
161 SWISS PARENTERALS LTD SYNER MEDICO PVT LTD Entity of related party Any other transaction Trade receivables 0 NA 0 1300000 0
162 ERIS LIFESCIENCES LTD Kanchan Pharma Private Limited Entity of related party Sale of goods or services 2000000000 Approved on 17 May 2023 114500000 44000000 148100000
163 ERIS THERAPEUTICS LTD Kanchan Pharma Private Limited Entity of related party Any other transaction Sales return 2000000000 Approved on 17 May 2023 16100000 901300000 174400000
164 ERIS HEALTHCARE PVT LTD Kanchan Pharma Private Limited Entity of related party Sale of goods or services 2000000000 Approved on 17 May 2023 385600000 0 432100000
165 ERIS LIFESCIENCES LTD Kanchan Pharma Private Limited Entity of related party Any other transaction Commission 2000000000 Approved on 17 May 2023 6400000 0 3600000
166 ERIS THERAPEUTICS LTD Kanchan Pharma Private Limited Entity of related party Any other transaction Commission 2000000000 Approved on 17 May 2023 4600000 0 1100000
167 ERIS M.J. BIOPHARM PVT LTD Kanchan Pharma Private Limited Entity of related party Any other transaction Commission 2000000000 Approved on 17 May 2023 200000 0 700000
168 ERIS LIFESCIENCES LTD Kanchan Pharma Private Limited Entity of related party Any other transaction Reimbursement of expenses 2000000000 Approved on 17 May 2023 1200000 0 0
169 ERIS THERAPEUTICS LTD Kanchan Pharma Private Limited Entity of related party Any other transaction Reimbursement of expenses 2000000000 Approved on 17 May 2023 300000 0 0
170 ERIS M.J. BIOPHARM PVT LTD Kanchan Pharma Private Limited Entity of related party Any other transaction Reimbursement of expenses 2000000000 Approved on 17 May 2023 2700000 0 0
171 ERIS LIFESCIENCES LTD Shah & Co Entity of related party Sale of goods or services 2000000000 Approved on 17 May 2023 1000000 100000 100000
172 ERIS THERAPEUTICS LTD Shah & Co Entity of related party Sale of goods or services 2000000000 Approved on 17 May 2023 500000 0 100000
173 ERIS LIFESCIENCES LTD Shah & Co Entity of related party Any other transaction Commission 2000000000 Approved on 17 May 2023 3500000 0 600000
174 ERIS THERAPEUTICS LTD Shah & Co Entity of related party Any other transaction Commission 2000000000 Approved on 17 May 2023 2200000 0 100000
Total value of transaction during the reporting period 39431200000





Format for Disclosing Outstanding Default on Loans and Debt Securities

Sr. No. Particulars Amount Remarks
1. Loans / revolving facilities like cash credit from banks / financial institutions
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
2. Unlisted debt securities i.e. NCDs and NCRPS
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
3. Total financial indebtedness of the listed entity including short-term and long-term debt